Skip to main content
Logo
European Innovation Council
private sector

Resistell AG

Rapid diagnostic for bacterial SEPSIS and AMR urgently needed for ICU patients in COVID-19-like epidemics

Resistell AG logo

Overview

Description

Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. The firm's offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, Resistell reduces the time taken to get a result from days to minutes. The company provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.

 

Website
Invested amount

EUR 2,300,000

Founded

2018

Project
Country
Switzerland
Theme
Health